vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and COLLEGIUM PHARMACEUTICAL, INC (COLL). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $205.4M, roughly 1.8× COLLEGIUM PHARMACEUTICAL, INC). COLLEGIUM PHARMACEUTICAL, INC runs the higher net margin — 8.3% vs -0.8%, a 9.0% gap on every dollar of revenue. On growth, COLLEGIUM PHARMACEUTICAL, INC posted the faster year-over-year revenue change (12.9% vs 9.4%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $36.1M). Over the past eight quarters, COLLEGIUM PHARMACEUTICAL, INC's revenue compounded faster (19.1% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
ASIX vs COLL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $205.4M |
| Net Profit | $-2.8M | $17.0M |
| Gross Margin | 7.6% | 62.5% |
| Operating Margin | -0.7% | 29.6% |
| Net Margin | -0.8% | 8.3% |
| Revenue YoY | 9.4% | 12.9% |
| Net Profit YoY | -892.9% | 35.3% |
| EPS (diluted) | $-0.11 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $205.4M | ||
| Q3 25 | $374.5M | $209.4M | ||
| Q2 25 | $410.0M | $188.0M | ||
| Q1 25 | $377.8M | $177.8M | ||
| Q4 24 | $329.1M | $181.9M | ||
| Q3 24 | $398.2M | $159.3M | ||
| Q2 24 | $453.5M | $145.3M | ||
| Q1 24 | $336.8M | $144.9M |
| Q4 25 | $-2.8M | $17.0M | ||
| Q3 25 | $-2.6M | $31.5M | ||
| Q2 25 | $31.4M | $12.0M | ||
| Q1 25 | $23.3M | $2.4M | ||
| Q4 24 | $352.0K | $12.5M | ||
| Q3 24 | $22.3M | $9.3M | ||
| Q2 24 | $38.9M | $19.6M | ||
| Q1 24 | $-17.4M | $27.7M |
| Q4 25 | 7.6% | 62.5% | ||
| Q3 25 | 6.8% | 61.7% | ||
| Q2 25 | 14.3% | 57.7% | ||
| Q1 25 | 14.2% | 54.8% | ||
| Q4 24 | 3.4% | 54.0% | ||
| Q3 24 | 14.4% | 60.8% | ||
| Q2 24 | 17.9% | 62.5% | ||
| Q1 24 | 0.9% | 63.1% |
| Q4 25 | -0.7% | 29.6% | ||
| Q3 25 | -0.9% | 29.7% | ||
| Q2 25 | 7.7% | 18.7% | ||
| Q1 25 | 7.7% | 12.2% | ||
| Q4 24 | -3.9% | 20.9% | ||
| Q3 24 | 7.5% | 21.9% | ||
| Q2 24 | 11.5% | 32.7% | ||
| Q1 24 | -7.0% | 34.1% |
| Q4 25 | -0.8% | 8.3% | ||
| Q3 25 | -0.7% | 15.0% | ||
| Q2 25 | 7.7% | 6.4% | ||
| Q1 25 | 6.2% | 1.4% | ||
| Q4 24 | 0.1% | 6.9% | ||
| Q3 24 | 5.6% | 5.9% | ||
| Q2 24 | 8.6% | 13.5% | ||
| Q1 24 | -5.2% | 19.1% |
| Q4 25 | $-0.11 | $0.48 | ||
| Q3 25 | $-0.10 | $0.84 | ||
| Q2 25 | $1.15 | $0.34 | ||
| Q1 25 | $0.86 | $0.07 | ||
| Q4 24 | $0.02 | $0.36 | ||
| Q3 24 | $0.82 | $0.27 | ||
| Q2 24 | $1.43 | $0.52 | ||
| Q1 24 | $-0.65 | $0.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $386.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $815.2M | $301.7M |
| Total Assets | $1.7B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $386.7M | ||
| Q3 25 | $23.7M | $285.9M | ||
| Q2 25 | $18.4M | $222.2M | ||
| Q1 25 | $8.3M | $197.8M | ||
| Q4 24 | $19.6M | $162.8M | ||
| Q3 24 | $17.3M | $120.0M | ||
| Q2 24 | $12.1M | $271.6M | ||
| Q1 24 | $20.6M | $318.0M |
| Q4 25 | $815.2M | $301.7M | ||
| Q3 25 | $818.2M | $274.8M | ||
| Q2 25 | $823.7M | $232.2M | ||
| Q1 25 | $794.4M | $234.4M | ||
| Q4 24 | $774.6M | $228.8M | ||
| Q3 24 | $766.4M | $234.3M | ||
| Q2 24 | $746.6M | $216.6M | ||
| Q1 24 | $713.2M | $222.2M |
| Q4 25 | $1.7B | $1.7B | ||
| Q3 25 | $1.7B | $1.6B | ||
| Q2 25 | $1.6B | $1.6B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.7B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.1B | ||
| Q1 24 | $1.5B | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $123.0M |
| Free Cash FlowOCF − Capex | $36.1M | $122.4M |
| FCF MarginFCF / Revenue | 10.0% | 59.6% |
| Capex IntensityCapex / Revenue | 7.7% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 7.25× |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $327.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $123.0M | ||
| Q3 25 | $26.6M | $78.4M | ||
| Q2 25 | $21.1M | $72.4M | ||
| Q1 25 | $11.4M | $55.4M | ||
| Q4 24 | $64.2M | $84.6M | ||
| Q3 24 | $57.3M | $-9.0M | ||
| Q2 24 | $50.2M | $67.4M | ||
| Q1 24 | $-36.2M | $61.9M |
| Q4 25 | $36.1M | $122.4M | ||
| Q3 25 | $66.0K | $78.3M | ||
| Q2 25 | $-7.2M | $72.4M | ||
| Q1 25 | $-22.6M | $54.6M | ||
| Q4 24 | $29.8M | $84.1M | ||
| Q3 24 | $26.8M | $-9.2M | ||
| Q2 24 | $16.7M | $67.1M | ||
| Q1 24 | $-71.6M | $61.4M |
| Q4 25 | 10.0% | 59.6% | ||
| Q3 25 | 0.0% | 37.4% | ||
| Q2 25 | -1.7% | 38.5% | ||
| Q1 25 | -6.0% | 30.7% | ||
| Q4 24 | 9.1% | 46.2% | ||
| Q3 24 | 6.7% | -5.8% | ||
| Q2 24 | 3.7% | 46.2% | ||
| Q1 24 | -21.3% | 42.3% |
| Q4 25 | 7.7% | 0.3% | ||
| Q3 25 | 7.1% | 0.1% | ||
| Q2 25 | 6.9% | 0.0% | ||
| Q1 25 | 9.0% | 0.4% | ||
| Q4 24 | 10.4% | 0.3% | ||
| Q3 24 | 7.7% | 0.2% | ||
| Q2 24 | 7.4% | 0.2% | ||
| Q1 24 | 10.5% | 0.4% |
| Q4 25 | — | 7.25× | ||
| Q3 25 | — | 2.49× | ||
| Q2 25 | 0.67× | 6.05× | ||
| Q1 25 | 0.49× | 22.92× | ||
| Q4 24 | 182.29× | 6.75× | ||
| Q3 24 | 2.57× | -0.96× | ||
| Q2 24 | 1.29× | 3.44× | ||
| Q1 24 | — | 2.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
COLL
Segment breakdown not available.
